BASEPAIR, INC.

NEW YORK, NY · Founded 2013 · Biotech · Private

EpiBeacon, a serverless cloud platform for rapid tertiary analysis, visualization, and comparative analysis of epigenomic sequencing data

Claim this profile

Follows are private to you and power your alerts

Updated · basepair.bio

Sector
Biotech
Headquarters
NEW YORK, NY
Founded
2013
Latest Form D
$1.1M, Sep 2021
Total capital
$2.5M
Federal grants
$647K
2 awards · 2019–2020
Rank in peer group#16 of 48
Private capital raised
$1.8M
2 Form D · last Sep 2021
61 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

2018201920202021FEDERAL ↑EQUITY ↓Cumulative $2.5M$299K$348K1st Form D$700K2nd Form D$1.1M
2018201920202021FEDERAL ↑EQUITY ↓Cumulative $2.5M$299K$348K1st Form D$700K2nd Form D$1.1M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$1.1M
  • Federal grantHealth and Human S · Phase I · Realtime visualization and analytics of epigenomic data using a serverless architecture$348K
  • Federal grantHealth and Human S · Phase I · PiNDA - Fully integrated software platform for Preimplantation Genetic Testing - Aneuploidy (PGT-A)$299K
  • Private capital raisedForm D · SEC · 1st filing$700K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 48 peers

Line = median

Biotech · Platform

  • Federal grants#16 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • AMIT SINHAResearcherExecutive Officer, DirectorLinked by $647K in grants as PI

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • AcelyrinSimilar federal contract value in Biotech · null in contracts
  • Cour PharmaceuticalSimilar federal contract value in Biotech · null in contracts
  • Paragon Bioservices, Inc.Similar federal contract value in Biotech · null in contracts
  • ADVANTAGE THERAPEUTICS, INCSimilar federal contract value in Biotech · null in contracts
  • ENVISAGENICS INCSimilar federal contract value in Biotech · null in contracts
  • Quralis CorporationSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .